drugset
drugset / Trial / NCT02185820

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

NCT02185820 ↗

Phase 1/2 Completed 57 enrolled European Myeloma Network B.V. University of Turin, Italy · collab
NaSingle-groupOpen-labelTreatment

Summary

This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations in relapsed and/or refractory Multiple Myeloma (MM) patients.

Timeline

Start
2014-06
Primary completion
2015-07
Completion
2023-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carfilzomib Other / unclassified 27 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 36 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 45 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 56 mg/m2 Intravenous
Background Dexamethasone Small molecule 20 mg —
Background Pomalidomide Other / unclassified 4 mg —

Indications

plasma cell myeloma